Wholesale Respiratory Devices for Costa Rica

CAFTA-DR (Central America-Dominican Republic Free Trade Agreement) has been in force since 2009 and provides preferential duty treatment on qualifying U.S.-origin medical devices. Most respiratory therapy equipment enters at 0% or near-zero tariff rates with a valid Certificate of Origin from the U.S. manufacturer.

SysMed includes CAFTA-DR certificates of origin with every shipment, pre-formatted for Costa Rica's Dirección General de Aduanas. For distributors evaluating landed costs, the duty elimination — combined with Costa Rica's FDA recognition pathway — makes U.S.-sourced respiratory devices significantly more competitive than European or Asian alternatives on both a cost and time-to-market basis.

Yes — and it's one of the strongest recognition pathways in Latin America. Since 2011, Costa Rica's Ministerio de Salud (through its DRPIS division) approves devices already cleared by the U.S. FDA without requiring a separate technical evaluation. No redundant clinical reviews, no additional efficacy testing.

You still need to file formally: Certificates of Free Sale, FDA 510(k) documentation, ISO 13485 certificates, and Spanish-language labeling. But eliminating the independent technical review collapses the timeline dramatically compared to markets like Argentina (60–120 days for Class III) or Uruguay (6–12 months). Every Resvent device in SysMed's portfolio qualifies for this expedited route.

Strategically, yes. Costa Rica is a member of SICA (Central American Integration System), which is progressively harmonizing medical device regulatory standards across the region — including Guatemala, Honduras, El Salvador, Nicaragua, and the Dominican Republic.

While SICA harmonization isn't yet at the point of mutual recognition (each country still requires its own registration), having an established Costa Rica registration demonstrates regional regulatory familiarity and provides documentation that translates well across SICA member processes. For distributors evaluating a multi-country Central American strategy, Costa Rica is typically the best first market due to its FDA recognition pathway and CAFTA-DR duty access.

Costa Rica has the highest asthma prevalence in Central America at 30% — nearly double the 17% regional average. COPD affects 9% of adults over 40, with an 88.7% underdiagnosis rate — meaning the vast majority of COPD cases aren't yet captured in the treatment system.

As diagnostic capacity expands under the CCSS's infrastructure investment plan, more patients will enter the treatment pipeline, driving institutional demand for ventilators, CPAP, and BiPAP devices. For distributors, this creates a growing market with predictable trajectory: diagnosed prevalence is rising not because the disease is spreading, but because detection is improving. SysMed helps partners align inventory planning with this demand curve.

The CCSS (Caja Costarricense de Seguro Social) dominates Costa Rica's healthcare market. It provides universal coverage, operates 29 hospitals and over 1,000 EBAIS primary care centers, and manages more than 90% of public healthcare delivery. When the CCSS procures respiratory equipment, it buys at national scale through centralized tender processes.

These tenders follow structured timelines with specific documentation, pricing, and delivery requirements. The CCSS has committed USD 3B+ in infrastructure investment through 2030, which includes expansion of respiratory care capacity. For distributors, this means growing tender volumes and multi-year supply opportunities. SysMed helps partners prepare CCSS tender documentation, including product specifications, registration evidence, and volume pricing proposals.